噻唑烷二酮类改善2型糖尿病合并急性肾脏疾病患者结局
本研究利用TriNetX平台数据,评估2型糖尿病合并急性肾脏疾病(AKD)患者在AKD诊断后90天内使用噻唑烷二酮类(TZD)对预后的影响。经倾向评分匹配后,TZD组全因死亡、主要不良心血管事件(MACE)和主要不良肾脏事件(MAKE)风险均低于对照组。
要点
- 在2型糖尿病合并AKD患者中,AKD期间使用TZD与全因死亡风险降低相关(HR 0.68)。
- TZD使用与MACE风险降低相关(HR 0.68)及MAKE风险降低相关(HR 0.75)。
- 作者认为TZD可能对管理此类患者的心血管事件有潜在益处。
核心结论
- 在2型糖尿病合并AKD患者中,TZD显著降低死亡、心血管事件和肾脏相关不良事件风险,提示TZD使用可能对管理心血管事件有潜在益处。
研究设计与样本
- 利用TriNetX平台(2022年9月30日前)数据,纳入2型糖尿病合并AKD诊断后90天内接受TZD治疗的患者,采用1:1倾向评分匹配(PSM),计算风险比(HR)及95%置信区间。
- 在263,101例AKD合并T2DM患者中,识别出2723例(1.03%)在AKD期间使用TZD;经PSM后,TZD组最终队列包含2555例,男性占53.82%,平均年龄64.0±13.5岁。
主要发现
- 中位随访1.5年期间,TZD组全因死亡风险HR为0.68(95%CI 0.57-0.81)。
- TZD组MACE风险HR为0.68(95%CI 0.58-0.80)。
- TZD组MAKE风险HR为0.75(95%CI 0.66-0.86)。
临床怎么用
- 原文结论未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Patients with diabetes are prone to acute kidney injury with the potential transition to chronic kidney disease. Few studies have investigated the role of thiazolidinedione (TZD) in these patients under acute kidney disease (AKD) phase. OBJECTIVE: We sought to examine whether using TZD during AKD could reduce the risk of future major adverse outcomes. DESIGN AND METHODS: We employed the TriNetX platform before September 30, 2022, for TZD administration to patients with type 2 diabetes mellitus (T2DM) within 90 days of an AKD diagnosis. Clinical endpoints include the risk of all-cause mortality, major adverse cardiovascular events (MACE), and major adverse kidney events (MAKE). Hazard ratios (HRs) and 95% confidence intervals were calculated with 1:1 ratio propensity score matching (PSM). RESULTS: Among the cohort of 263,101 patients with AKD and T2DM, we identified 2723 individuals (1.03%) who were TZD users during the AKD period. After PSM, the final cohort of TZD users included 2555 individuals, with 53.82% being male and a mean age of 64.0 ± 13.5 years. Over a median follow-up period of 1.5 years, the TZD group exhibited a lower risk across various outcomes, with HRs of 0.68 [95% confidence interval (CI), 0.57-0.81] for all-cause mortality, 0.68 (95% CI, 0.58-0.80) for MACE, and 0.75 (95% CI, 0.66-0.86) for MAKE. CONCLUSION: TZD demonstrated a notable reduction in mortality, cardiovascular events, and kidney-related adverse events among T2DM patients with AKD. These findings suggest a potential benefit of TZD usage for managing cardiovascular events in T2DM patients with AKD.
引用
- Chang LY, Liao HW, Chen JY, et al. Enhanced Outcomes in Type 2 Diabetes Patients With Acute Kidney Disease Through Thiazolidinedione. J Clin Endocrinol Metab. 2025. PMID: 39535770. doi:10.1210/clinem/dgae796
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。